What focal therapy changes<\/h2>\n\n\n\n
Focal therapy destroys only the part of the prostate containing clinically important cancer. Doctors can use high-intensity focused ultrasound, known as HIFU, to heat the tumor or cryotherapy to freeze it, while leaving much of the gland untouched.<\/p>\n\n\n\n
Read More: When your blood sugar spikes out of nowhere, these five simple habits could help you take back control of your diabetes<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThat differs from radical prostatectomy, which removes the prostate, and radiation therapy, which treats the whole gland. By sparing nearby tissue, doctors may better protect the nerves and muscles involved in erections, urination, and bowel function.<\/p>\n\n\n\n
Previous evidence has linked focal therapy with a roughly fivefold lower risk of serious urinary, sexual, and rectal side effects. The new paper focused on cancer control, however, and did not report long-term functional outcomes. That gap still matters.<\/p>\n\n\n\n
A decade of patient data<\/h2>\n\n\n\n
Dr. Alexander Light led the analysis with researchers from Imperial College London and Imperial College Healthcare NHS Trust. The team used prospective HEAT and ICE registry data from men treated with HIFU or cryotherapy at 14 U.K. hospitals between 2004 and 2024.<\/p>\n\n\n\n
At 10 years, the estimated prostate cancer death rate was 0.13% and the metastasis rate was 3.3%. Those figures resemble results reported for surgery and radiation in the separate ProtecT trial<\/a>, although differences between the studies mean this is context rather than direct proof of equality.<\/p>\n\n\n\nLight called the results \u201creally encouraging\u201d and said men with more aggressive disease also appeared to benefit. That is notable because focal therapy has often been viewed mainly as an option for lower-risk or narrowly located tumors.<\/p>\n\n\n\n![\"Medical](\"https:\/\/okdiario.com\/metabolic\/en\/wp-content\/uploads\/2026\/08\/focal-therapy-prostate-cancer-treatment-hifu.jpg\" "\\"\\"")
A large U.K. study reveals long-term cancer control and lower side effect risks for focal therapy in prostate cancer.<\/figcaption><\/figure>\n\n\n\nThe trade-off patients should know<\/h2>\n\n\n\n
Focal therapy is not always a one-and-done procedure. In the main analysis, about one-third of patients received another local treatment and 30% eventually underwent radical treatment such as surgery or radiation within 10 years.<\/p>\n\n\n\n
A secondary analysis allowed up to two focal sessions before counting the approach as unsuccessful. Under that definition, fewer than 9% later required radical treatment. Some men may avoid whole-gland therapy, but close monitoring<\/a> remains essential.<\/p>\n\n\n\n\n\n\nRead More: Xavi Batalla, regenerative medicine specialist: every morning I drink a juice of beetroot, carrot, orange, lemon, ginger and turmeric<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nProfessor Hashim Ahmed said the findings make \u201ca compelling case for more centers to offer this treatment.\u201d Even so, eligibility depends on the tumor\u2019s location, grade, size, and whether cancer is present in several parts of the prostate.<\/p>\n\n\n\n
Why NHS access remains limited<\/h2>\n\n\n\n
Public interest grew after Clarkson and former British prime minister Lord Cameron disclosed that they had received focal therapy after prostate cancer diagnoses. Both obtained treatment privately, highlighting an option that many NHS patients still cannot access locally.<\/p>\n\n\n\n
Around half to two-thirds of localized prostate cancers could be suitable for focal therapy, representing as many as 15,000 U.K. patients each year. Yet only about 1,000 men currently receive it annually, with most NHS providers concentrated in London and southeast England.<\/p>\n\n\n\n
The limited rollout reflects uncertainty over long-term outcomes and the lack of routine approval from the National Institute for Health and Care Excellence. <\/p>\n\n\n\n
On June 2, 2026, the U.K. government announced capital funding<\/a> to expand focal therapy alongside the TRANSFORM research program. For now, though, access can still depend heavily on where a patient lives.<\/p>\n\n\n\n
Light called the results \u201creally encouraging\u201d and said men with more aggressive disease also appeared to benefit. That is notable because focal therapy has often been viewed mainly as an option for lower-risk or narrowly located tumors.<\/p>\n\n\n\n Focal therapy is not always a one-and-done procedure. In the main analysis, about one-third of patients received another local treatment and 30% eventually underwent radical treatment such as surgery or radiation within 10 years.<\/p>\n\n\n\n A secondary analysis allowed up to two focal sessions before counting the approach as unsuccessful. Under that definition, fewer than 9% later required radical treatment. Some men may avoid whole-gland therapy, but close monitoring<\/a> remains essential.<\/p>\n\n\n\n Professor Hashim Ahmed said the findings make \u201ca compelling case for more centers to offer this treatment.\u201d Even so, eligibility depends on the tumor\u2019s location, grade, size, and whether cancer is present in several parts of the prostate.<\/p>\n\n\n\n Public interest grew after Clarkson and former British prime minister Lord Cameron disclosed that they had received focal therapy after prostate cancer diagnoses. Both obtained treatment privately, highlighting an option that many NHS patients still cannot access locally.<\/p>\n\n\n\n Around half to two-thirds of localized prostate cancers could be suitable for focal therapy, representing as many as 15,000 U.K. patients each year. Yet only about 1,000 men currently receive it annually, with most NHS providers concentrated in London and southeast England.<\/p>\n\n\n\n The limited rollout reflects uncertainty over long-term outcomes and the lack of routine approval from the National Institute for Health and Care Excellence. <\/p>\n\n\n\n On June 2, 2026, the U.K. government announced capital funding<\/a> to expand focal therapy alongside the TRANSFORM research program. For now, though, access can still depend heavily on where a patient lives.<\/p>\n\n\n\nThe trade-off patients should know<\/h2>\n\n\n\n
Read More: Xavi Batalla, regenerative medicine specialist: every morning I drink a juice of beetroot, carrot, orange, lemon, ginger and turmeric<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Why NHS access remains limited<\/h2>\n\n\n\n